← Eichor
Study identifier: NCT05899621 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Condition: Follicular Lymphoma  ·  Sponsor: Ruijin Hospital

PhaseN/A
Planned participants332
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study aims to observe and explore the efficacy and safety of obinutuzumab-based therapy for previously untreated follicular lymphoma

This description comes directly from the study's public registry record.

Talk to the study team

Weili Zhao, +862164370045  ·  +862164370045  ·  zwl_trial@163.com

Pengpeng Xu, PhD，MD  ·  +862164370045

Always discuss trial participation with your own doctor first.

Locations (1)

Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05899621